Skip to main content
. 2016 Jan 15;81(2):235–245. doi: 10.1111/bcp.12787

Figure 2.

Figure 2

The mean plasma concentration‐time profiles of ibrutinib following (n=8) A. Oral administration of 560 mg ibrutinib under fasted ( Inline graphic Treatment A) and fed ( Inline graphic Treatment B) conditions, and 140 mg ibrutinib under fed condition with grapefruit juice ( Inline graphic Treatment C). B. Ibrutinib following oral administration of 560 mg ibrutinib without grapefruit juice ( Inline graphic Treatment B) and dose‐normalized ibrutinib with grapefruit juice ( Inline graphic Treatment C).